Free Trial

180 Life Sciences (ATNF) FDA Events

180 Life Sciences logo
$0.89 +0.01 (+0.69%)
As of 10:59 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
FDA Events for 180 Life Sciences (ATNF)

This section highlights FDA-related milestones and regulatory updates for drugs developed by 180 Life Sciences (ATNF). Over the past two years, 180 Life Sciences has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Epidiolex. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

Epidiolex (cannabidiol) - FDA Regulatory Timeline and Events

Epidiolex (cannabidiol) is a drug developed by 180 Life Sciences for the following indication: Epilepsy with Myoclonic-Atonic Seizures (EMAS). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

180 Life Sciences FDA Events - Frequently Asked Questions

As of now, 180 Life Sciences (ATNF) has not received any FDA approvals for its therapy in the last two years.

In the past two years, 180 Life Sciences (ATNF) has reported FDA regulatory activity for Epidiolex (cannabidiol).

The most recent FDA-related event for 180 Life Sciences occurred on July 30, 2024, involving Epidiolex (cannabidiol). The update was categorized as "Top-line results," with the company reporting: "180 Life Sciences Corp. announced topline results from a clinical pharmacology study (the "Study"), that evaluated the uptake of cannabidiol (CBD) in a solid formulation which can be delivered as a pill orally."

Currently, 180 Life Sciences has one therapy (Epidiolex (cannabidiol)) targeting the following condition: Epilepsy with Myoclonic-Atonic Seizures (EMAS).

More FDA Event Resources from MarketBeat

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

This page (NASDAQ:ATNF) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners